Detection of cerebral metastases on magnetic resonance imaging

Intraindividual comparison of gadobutrol with gadopentetate dimeglumine

Nicoletta Anzalone, Simonetta Gerevini, Roberta Scotti, Paolo Vezzulli, Piero Picozzi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Contrast-enhanced magnetic resonance (MR) imaging with gadolinium-based contrast agents is widely used for the detection of cerebral metastases with standard contrast agents. Newer developments in MR contrast agents have led to a higher relaxivity and/or concentration for these agents. Purpose: To assess the effectiveness of a standard dose of 1.0 M gadobutrol compared with a standard dose of gadopentetate dimeglumine for the MR detection of brain metastases. Material and Methods: 27 patients with at least one cerebral metastasis were examined twice with contrast-enhanced MR imaging, using gadobutrol at 0.1 ml/kg and gadopentetate dimeglumine at 0.2 ml/kg (i.e., identical gadolinium dosage of 0.1 mmol/kg bodyweight). The interval between examinations was 18 hours, and the order of injection was fully randomized. Images were acquired using a three-dimensional (3D) fast gradient echo sequence, and evaluated in blinded fashion by two experienced neuroradiologists in consensus in terms of the total number of lesions detected at each examination in each patient and qualitatively in terms of the lesion conspicuity observed. Results: A total of 67 lesions were detected after gadobutrol compared with 65 lesions detected after gadopentetate dimeglumine. In two patients, a lesion was seen only after gadobutrol. Qualitative comparison of images revealed improved lesion conspicuity after gadobutrol in 10/27 cases compared with 0/27 cases after gadopentetate dimeglumine, and equivalent conspicuity in 17/27 cases (P=0.002, gadobutrol vs. gadopentetate dimeglumine). Conclusion:At equal gadolinium dosage, gadobutrol appears to offer significant advantages over gadopentetate dimeglumine for the visualization of brain metastases, with particular benefit for improving the conspicuity of detected lesions.

Original languageEnglish
Pages (from-to)933-940
Number of pages8
JournalActa Radiologica
Volume50
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

Gadolinium DTPA
Magnetic Resonance Imaging
Neoplasm Metastasis
Gadolinium
Contrast Media
Magnetic Resonance Spectroscopy
Brain
gadobutrol
Injections

Keywords

  • Adults
  • Brain
  • CNS
  • Contrast agents
  • Intravenous
  • Localization
  • MR imaging

ASJC Scopus subject areas

  • Medicine(all)
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Detection of cerebral metastases on magnetic resonance imaging : Intraindividual comparison of gadobutrol with gadopentetate dimeglumine. / Anzalone, Nicoletta; Gerevini, Simonetta; Scotti, Roberta; Vezzulli, Paolo; Picozzi, Piero.

In: Acta Radiologica, Vol. 50, No. 8, 2009, p. 933-940.

Research output: Contribution to journalArticle

@article{82a089194d8f4af8a949b9266721bf03,
title = "Detection of cerebral metastases on magnetic resonance imaging: Intraindividual comparison of gadobutrol with gadopentetate dimeglumine",
abstract = "Background: Contrast-enhanced magnetic resonance (MR) imaging with gadolinium-based contrast agents is widely used for the detection of cerebral metastases with standard contrast agents. Newer developments in MR contrast agents have led to a higher relaxivity and/or concentration for these agents. Purpose: To assess the effectiveness of a standard dose of 1.0 M gadobutrol compared with a standard dose of gadopentetate dimeglumine for the MR detection of brain metastases. Material and Methods: 27 patients with at least one cerebral metastasis were examined twice with contrast-enhanced MR imaging, using gadobutrol at 0.1 ml/kg and gadopentetate dimeglumine at 0.2 ml/kg (i.e., identical gadolinium dosage of 0.1 mmol/kg bodyweight). The interval between examinations was 18 hours, and the order of injection was fully randomized. Images were acquired using a three-dimensional (3D) fast gradient echo sequence, and evaluated in blinded fashion by two experienced neuroradiologists in consensus in terms of the total number of lesions detected at each examination in each patient and qualitatively in terms of the lesion conspicuity observed. Results: A total of 67 lesions were detected after gadobutrol compared with 65 lesions detected after gadopentetate dimeglumine. In two patients, a lesion was seen only after gadobutrol. Qualitative comparison of images revealed improved lesion conspicuity after gadobutrol in 10/27 cases compared with 0/27 cases after gadopentetate dimeglumine, and equivalent conspicuity in 17/27 cases (P=0.002, gadobutrol vs. gadopentetate dimeglumine). Conclusion:At equal gadolinium dosage, gadobutrol appears to offer significant advantages over gadopentetate dimeglumine for the visualization of brain metastases, with particular benefit for improving the conspicuity of detected lesions.",
keywords = "Adults, Brain, CNS, Contrast agents, Intravenous, Localization, MR imaging",
author = "Nicoletta Anzalone and Simonetta Gerevini and Roberta Scotti and Paolo Vezzulli and Piero Picozzi",
year = "2009",
doi = "10.1080/02841850903095385",
language = "English",
volume = "50",
pages = "933--940",
journal = "Acta Radiologica",
issn = "0284-1851",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Detection of cerebral metastases on magnetic resonance imaging

T2 - Intraindividual comparison of gadobutrol with gadopentetate dimeglumine

AU - Anzalone, Nicoletta

AU - Gerevini, Simonetta

AU - Scotti, Roberta

AU - Vezzulli, Paolo

AU - Picozzi, Piero

PY - 2009

Y1 - 2009

N2 - Background: Contrast-enhanced magnetic resonance (MR) imaging with gadolinium-based contrast agents is widely used for the detection of cerebral metastases with standard contrast agents. Newer developments in MR contrast agents have led to a higher relaxivity and/or concentration for these agents. Purpose: To assess the effectiveness of a standard dose of 1.0 M gadobutrol compared with a standard dose of gadopentetate dimeglumine for the MR detection of brain metastases. Material and Methods: 27 patients with at least one cerebral metastasis were examined twice with contrast-enhanced MR imaging, using gadobutrol at 0.1 ml/kg and gadopentetate dimeglumine at 0.2 ml/kg (i.e., identical gadolinium dosage of 0.1 mmol/kg bodyweight). The interval between examinations was 18 hours, and the order of injection was fully randomized. Images were acquired using a three-dimensional (3D) fast gradient echo sequence, and evaluated in blinded fashion by two experienced neuroradiologists in consensus in terms of the total number of lesions detected at each examination in each patient and qualitatively in terms of the lesion conspicuity observed. Results: A total of 67 lesions were detected after gadobutrol compared with 65 lesions detected after gadopentetate dimeglumine. In two patients, a lesion was seen only after gadobutrol. Qualitative comparison of images revealed improved lesion conspicuity after gadobutrol in 10/27 cases compared with 0/27 cases after gadopentetate dimeglumine, and equivalent conspicuity in 17/27 cases (P=0.002, gadobutrol vs. gadopentetate dimeglumine). Conclusion:At equal gadolinium dosage, gadobutrol appears to offer significant advantages over gadopentetate dimeglumine for the visualization of brain metastases, with particular benefit for improving the conspicuity of detected lesions.

AB - Background: Contrast-enhanced magnetic resonance (MR) imaging with gadolinium-based contrast agents is widely used for the detection of cerebral metastases with standard contrast agents. Newer developments in MR contrast agents have led to a higher relaxivity and/or concentration for these agents. Purpose: To assess the effectiveness of a standard dose of 1.0 M gadobutrol compared with a standard dose of gadopentetate dimeglumine for the MR detection of brain metastases. Material and Methods: 27 patients with at least one cerebral metastasis were examined twice with contrast-enhanced MR imaging, using gadobutrol at 0.1 ml/kg and gadopentetate dimeglumine at 0.2 ml/kg (i.e., identical gadolinium dosage of 0.1 mmol/kg bodyweight). The interval between examinations was 18 hours, and the order of injection was fully randomized. Images were acquired using a three-dimensional (3D) fast gradient echo sequence, and evaluated in blinded fashion by two experienced neuroradiologists in consensus in terms of the total number of lesions detected at each examination in each patient and qualitatively in terms of the lesion conspicuity observed. Results: A total of 67 lesions were detected after gadobutrol compared with 65 lesions detected after gadopentetate dimeglumine. In two patients, a lesion was seen only after gadobutrol. Qualitative comparison of images revealed improved lesion conspicuity after gadobutrol in 10/27 cases compared with 0/27 cases after gadopentetate dimeglumine, and equivalent conspicuity in 17/27 cases (P=0.002, gadobutrol vs. gadopentetate dimeglumine). Conclusion:At equal gadolinium dosage, gadobutrol appears to offer significant advantages over gadopentetate dimeglumine for the visualization of brain metastases, with particular benefit for improving the conspicuity of detected lesions.

KW - Adults

KW - Brain

KW - CNS

KW - Contrast agents

KW - Intravenous

KW - Localization

KW - MR imaging

UR - http://www.scopus.com/inward/record.url?scp=70350020616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350020616&partnerID=8YFLogxK

U2 - 10.1080/02841850903095385

DO - 10.1080/02841850903095385

M3 - Article

VL - 50

SP - 933

EP - 940

JO - Acta Radiologica

JF - Acta Radiologica

SN - 0284-1851

IS - 8

ER -